Autoimmune diabetes vaccine (Diamyd) - Diamyd Medical

Drug Profile

Autoimmune diabetes vaccine (Diamyd) - Diamyd Medical

Alternative Names: Antigen-based therapy (ABT) - Diamyd Medical; Diabetes-mellitus-vaccine-Diamyd-Medical; Diabetes-mellitus-vaccine-Diamyd-Therapeutics; Diamyd; GAD-65 - Diamyd Medical; GAD-Alum vaccine; GAD-Alum vaccine - Diamyd Medical; GAD-antigen therapy (Diamyd); rhGAD65 - Diamyd Medical

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Diamyd Medical
  • Developer Diamyd Medical AB; Linkoping University; Lund University; University of Alabama at Birmingham
  • Class Antihyperglycaemics; Diabetes mellitus vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Type 1 diabetes mellitus
  • Phase II Latent autoimmune diabetes in adults

Most Recent Events

  • 21 Sep 2017 Diamyd Medical receives approval from the Spanish and Czech Republic Competent Authorities and the relevant Ethics Committees to initiate the phase II DIAGNODE-2 trial in Czech Republic and Spain
  • 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
  • 10 Aug 2017 Diamyd Medical and Cardiff University collaborate on a clinical trial for Type-1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top